Receptor agonist therapy offers targeted action, predictable dose responses, and potential reduction of adverse effects
This is a major reason patients compare prescription GLP-1 vs compounded weight loss injections before starting treatment
Furthermore, most patients who start treatment with GLP-1RA for obesity discontinue treatment within 1 year because of side effects, high cost, or reaching a plateau in weight loss [106]
Includes dual and triple-agonist formulations such as Retatrutide, Tirzepatide and Semaglutide for preclinical investigation
If approved, Retatrutide dosage would be good for long-term body weight management when used with lifestyle support
Please update your browser for more security and a better experience